Metropolitan Life Insurance Company (MetLife)’s Design Therapeutics DSGN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,016	Closed	-$12.7K	–	2411
2023 Q2	$12.7K	Hold	2,016	–	–	﹤0.01%	2168
2023 Q1	$11.6K	Sell	2,016 -233	-10%	-$1.74K	﹤0.01%	2101
2022 Q4	$23.1K	Buy	2,249 +222	+11%	+$3.01K	﹤0.01%	1934
2022 Q3	$33.9K	Hold	2,027	–	–	﹤0.01%	1723
2022 Q2	$28.4K	Hold	2,027	–	–	﹤0.01%	1853
2022 Q1	$32.7K	Sell	2,027 -6,021	-75%	-$92.2K	﹤0.01%	1833
2021 Q4	$172K	Buy	+8,048	New	+$138K	﹤0.01%	2126

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s DSGN Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Design Therapeutics (DSGN) in Q3 2023, closing a stake of 2,016 shares — an estimated $12.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DSGN in Q4 2021 and held it in 7 quarters. The position peaked at $172K in Q4 2021. 87 funds tracked by Wall St. Rank hold DSGN as of Q3 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Design Therapeutics position as of Q3 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,016 Design Therapeutics shares in Q3 2023, an estimated $12.7K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Design Therapeutics in Q4 2021 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Design Therapeutics position peaked at $172K in Q4 2021.
87 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.